241 related articles for article (PubMed ID: 8442093)
1. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1.
Ferrara JL; Abhyankar S; Gilliland DG
Transplant Proc; 1993 Feb; 25(1 Pt 2):1216-7. PubMed ID: 8442093
[No Abstract] [Full Text] [Related]
2. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens.
Abhyankar S; Gilliland DG; Ferrara JL
Transplantation; 1993 Dec; 56(6):1518-23. PubMed ID: 8279027
[TBL] [Abstract][Full Text] [Related]
3. Immunopathogenesis of GVHD.
Imamura M; Tanaka J; Hashino S; Kobayashi S; Imai K; Asaka M; Kasai M
Transplant Proc; 1996 Jun; 28(3):1181-3. PubMed ID: 8658619
[No Abstract] [Full Text] [Related]
4. Murine models of graft-versus-host disease with features of scleroderma.
Charley MR; Deng JS
Immunol Ser; 1989; 46():625-40. PubMed ID: 2488872
[No Abstract] [Full Text] [Related]
5. Interleukin-1 or tumor necrosis factor-alpha antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice.
Vallera DA; Taylor PA; Vannice JL; Panoskaltsis-Mortari A; Blazar BR
Transplantation; 1995 Dec; 60(11):1371-4. PubMed ID: 8525541
[TBL] [Abstract][Full Text] [Related]
6. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the repertoire of T-cell lines and clones specific for minor histocompatibility antigens derived from immunized mice and from mice developing a graft-versus-host reaction.
Bruley-Rosset M; Miconnet I; Roger T; Seman M; Halle-Pannenko O
Transplant Proc; 1993 Feb; 25(1 Pt 1):94-5. PubMed ID: 8438503
[No Abstract] [Full Text] [Related]
8. The absence of donor-derived IL-13 exacerbates the severity of acute graft-versus-host disease following allogeneic bone marrow transplantation.
Hildebrandt GC; Choi SW; Mueller G; Olkiewicz KM; Moore BB; Cooke KR
Pediatr Blood Cancer; 2008 Apr; 50(4):911-4. PubMed ID: 17455319
[TBL] [Abstract][Full Text] [Related]
9. Antigen-specific T-lymphocyte responses in acute and chronic syngeneic graft-versus-host disease.
Hess AD; Thoburn CJ; Miura Y; Bright EC
Transplant Proc; 2005; 37(1):53-6. PubMed ID: 15808545
[TBL] [Abstract][Full Text] [Related]
10. Analysis of V beta T-cell receptor repertoire of effector mechanisms in acute and chronic graft versus host disease.
Fischer AC; Ruvolo PP; Horwitz LR; Hess AD
Transplant Proc; 1995 Feb; 27(1):1366-9. PubMed ID: 7878914
[No Abstract] [Full Text] [Related]
11. A two-phase pathogenesis of graft-versus-host disease in mice.
van Leeuwen L; Guiffre A; Atkinson K; Rainer SP; Sewell WA
Bone Marrow Transplant; 2002 Jan; 29(2):151-8. PubMed ID: 11850710
[TBL] [Abstract][Full Text] [Related]
12. Unexpected role of TNF-alpha in graft versus host reaction (GVHR): donor-derived TNF-alpha suppresses GVHR via inhibition of IFN-gamma-dependent donor type-1 immunity.
Yamamoto S; Tsuji T; Matsuzaki J; Zhange Y; Chamoto K; Kosaka A; Togashi Y; Sekikawa K; Sawada K; Takeshima T; Koike T; Nishimura T
Int Immunol; 2004 Jun; 16(6):811-7. PubMed ID: 15126416
[TBL] [Abstract][Full Text] [Related]
13. Induction and analysis of lethal graft-versus-host disease in tolerant mice.
Végh P; Vizler C; Jánossy T; Savelkoul HF; Nyirati I; Benner R
Transplant Proc; 1996 Jun; 28(3):1241-3. PubMed ID: 8658641
[No Abstract] [Full Text] [Related]
14. [Graft versus host disease].
Volc-Platzer B
Hautarzt; 1992 Oct; 43(10):669-77. PubMed ID: 1428880
[No Abstract] [Full Text] [Related]
15. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation.
Holler E; Kolb HJ; Hintermeier-Knabe R; Mittermüller J; Thierfelder S; Kaul M; Wilmanns W
Transplant Proc; 1993 Feb; 25(1 Pt 2):1234-6. PubMed ID: 8442099
[No Abstract] [Full Text] [Related]
16. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
17. Acute graft-versus-host disease does not require alloantigen expression on host epithelium.
Teshima T; Ordemann R; Reddy P; Gagin S; Liu C; Cooke KR; Ferrara JL
Nat Med; 2002 Jun; 8(6):575-81. PubMed ID: 12042807
[TBL] [Abstract][Full Text] [Related]
18. Cytokines in veno-occlusive disease of the liver after bone marrow transplantation.
Remberger M; Ringdén O
Transplant Proc; 1995 Dec; 27(6):3533-4. PubMed ID: 8540087
[No Abstract] [Full Text] [Related]
19. Functional divergence of antigen-specific T-lymphocyte responses in syngeneic graft-versus-host disease.
Thoburn CJ; Miura Y; Bright EC; Hess AD
Biol Blood Marrow Transplant; 2004 Sep; 10(9):591-603. PubMed ID: 15319771
[TBL] [Abstract][Full Text] [Related]
20. Th1 cytokines and NK cells participate in the development of murine syngeneic graft-versus-host disease.
Flanagan DL; Jennings CD; Bryson JS
J Immunol; 1999 Aug; 163(3):1170-7. PubMed ID: 10415011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
